RostaingLBunnapradistSGrinyóJM, et al.Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in de novo kidney transplant recipients: two-year results of phase 3, double-blind, randomized trial. Am J Kidney Dis. 2016;67(4):648–659. doi:10.1053/j.ajkd.2015.10.024.
2.
TremblaySNigroVWeinbergJWoodleESAllowayRR. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study. Am J Transplant. 2017;17(2):432–442. doi:10.1111/ajt.13935.
3.
WadaKTakadaMUedaT, et al.Drug interactions between tacrolimus and phenytoin in Japanese heart transplant recipients: 2 case reports. Int J Clin Pharmacol Ther. 2007;45(9):524–528.
4.
ThelenKDressmanJB. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol. 2009;61(5):541–558. doi:10.1211/jpp/61.05.002.
5.
WilliamsonBLPurkayasthaSHunterCL, et al.Quantitative protein determination for CYP induction via LC-MS/MS. Proteomics. 2011;11(1):33–41. doi:10.1002/pmic.201000456.
